UltiMaker and Bioactivx Signed Medical Printing Agreement
The companies have partnered to 3D print artificial skin substitutes for on-demand medical treatment.
Updated on Sept. 19, 2026 in Healthcare
Live Poll
Do you believe on-demand medical manufacturing at clinics will improve patient care?
UltiMaker and Bioactivx signed a memorandum of understanding to deploy 3D printing of medical products closer to treatment sites. This follows Bioactivx receiving Health Sciences Authority approval for its synthetic, animal-free Bioactiv Matrix skin substitute.
Why it matters
The collaboration aims to reduce the time between injury and treatment by shifting production from centralized factories to local 3D printing configurations. This decentralized approach could fundamentally change how artificial skin is supplied to clinical settings.
Bioactivx earned ISO 13485 certification for end-use medical manufacturing and opened a certified cleanroom facility. The product is also currently tracked at a World Health Organization medical device maturity level of 4.
The players
UltiMaker
UltiMaker is a global manufacturer of professional-grade 3D printing equipment and software solutions.
Bioactivx
Bioactivx is a Singapore-based biotechnology company specializing in the development of advanced synthetic skin substitutes.
Health Sciences Authority
The Health Sciences Authority is the Singaporean government agency responsible for regulating medical devices and health products.
The details
Bioactivx produces the Bioactiv Matrix using a proprietary active-ingredient filament on a fleet of UltiMaker 3D printers. The manufacturing process takes place entirely within a certified cleanroom facility to ensure medical-grade standards.
Timeline
September 19, 2026: The companies announced their memorandum of understanding and the HSA approval.
2025: Cutiss reported positive interim clinical trial results.
Market Landscape
The push for decentralized medical manufacturing reflects a broader industry shift toward point-of-care production. By adopting ISO 13485 standards, the partners are positioning themselves to compete with legacy supply chains that rely on centralized factory models.
This partnership aims to make advanced skin substitutes more accessible to clinicians for immediate patient care. While currently limited to Singapore, the planned global regulatory submissions suggest future availability for patients in the U.S., the EU, and Australia.
The takeaway
The move toward on-demand medical printing represents a significant step in reducing logistical delays for critical supplies. Implementing this technology could eventually allow hospitals to produce life-saving materials on-site rather than awaiting long-distance shipments.
What happens next
The companies plan to refine their 3D printing configuration for decentralized deployment over the coming months.
Further reading
For more on industry developments, visit our Healthcare section.
Source note: This article includes information reported by 3D Printing Industry.
Live Poll
Do you believe on-demand medical manufacturing at clinics will improve patient care?
